อัปเดตที่ 1 จาก 1ล่าสุดวันที่ 1
A One-Person Shot Delayed Melanoma's Return. The Proof Is Still Missing.
Merck and Moderna say their personalized mRNA plus Keytruda met two recurrence endpoints in high-risk melanoma — but with no numbers, no safety data and no paper, scale and approval remain unproven.
สิ่งที่เราทราบในตอนแรก
- Phase 3 INTerpath-001 tested intismeran autogene plus Keytruda against Keytruda alone in completely resected stage IIB-IV melanoma and met recurrence-free and distant metastasis-free survival endpoints.
- Results were disclosed only as company topline statements, not a published or peer-reviewed data set.
- Intismeran is the most advanced program in a 50/50 Merck-Moderna partnership across tumor types.
ที่ยังไม่ชัดเจนในตอนนั้น
- No magnitude of benefit, hazard ratios, absolute risk reduction, overall survival, durability, safety details, cost, turnaround time, or FDA review timeline is established on this record.
- The exact enrollment number and the size and durability of the market move at a single agreed timepoint are not established.
สิ่งที่เราบอกว่าจะจับตา
- Peer-reviewed publication of the full Phase 3 data set with efficacy numbers and safety for the combination versus Keytruda alone.
- Any defined regulatory path and approval standard, plus evidence the individualized manufacturing process can scale.